CRNX
Price
$35.18
Change
-$0.68 (-1.90%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
3.38B
43 days until earnings call
DNTH
Price
$37.18
Change
-$0.69 (-1.82%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
1.51B
Interact to see
Advertisement

CRNX vs DNTH

Header iconCRNX vs DNTH Comparison
Open Charts CRNX vs DNTHBanner chart's image
Crinetics Pharmaceuticals
Price$35.18
Change-$0.68 (-1.90%)
Volume$47.5K
Capitalization3.38B
Dianthus Therapeutics
Price$37.18
Change-$0.69 (-1.82%)
Volume$22.9K
Capitalization1.51B
CRNX vs DNTH Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. DNTH commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Buy and DNTH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (CRNX: $35.86 vs. DNTH: $37.87)
Brand notoriety: CRNX and DNTH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 127% vs. DNTH: 56%
Market capitalization -- CRNX: $3.38B vs. DNTH: $1.51B
CRNX [@Biotechnology] is valued at $3.38B. DNTH’s [@Biotechnology] market capitalization is $1.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileDNTH’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • DNTH’s FA Score: 1 green, 4 red.
According to our system of comparison, DNTH is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 5 TA indicator(s) are bullish while DNTH’s TA Score has 5 bullish TA indicator(s).

  • CRNX’s TA Score: 5 bullish, 5 bearish.
  • DNTH’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DNTH is a better buy in the short-term than CRNX.

Price Growth

CRNX (@Biotechnology) experienced а +5.16% price change this week, while DNTH (@Biotechnology) price change was +1.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.31%. For the same industry, the average monthly price growth was +10.09%, and the average quarterly price growth was +53.86%.

Reported Earning Dates

CRNX is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+4.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($3.38B) has a higher market cap than DNTH($1.51B). DNTH YTD gains are higher at: 73.716 vs. CRNX (-29.865). DNTH has higher annual earnings (EBITDA): -129.49M vs. CRNX (-419.62M). CRNX has more cash in the bank: 1.2B vs. DNTH (257M). DNTH has less debt than CRNX: DNTH (1.33M) vs CRNX (49.9M). DNTH has higher revenues than CRNX: DNTH (4.85M) vs CRNX (1.39M).
CRNXDNTHCRNX / DNTH
Capitalization3.38B1.51B224%
EBITDA-419.62M-129.49M324%
Gain YTD-29.86573.716-41%
P/E RatioN/A3.24-
Revenue1.39M4.85M29%
Total Cash1.2B257M465%
Total Debt49.9M1.33M3,752%
FUNDAMENTALS RATINGS
CRNX vs DNTH: Fundamental Ratings
CRNX
DNTH
OUTLOOK RATING
1..100
1021
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
64
Fair valued
PROFIT vs RISK RATING
1..100
6226
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
5736
P/E GROWTH RATING
1..100
10061
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNTH's Valuation (64) in the null industry is in the same range as CRNX (88) in the Pharmaceuticals Major industry. This means that DNTH’s stock grew similarly to CRNX’s over the last 12 months.

DNTH's Profit vs Risk Rating (26) in the null industry is somewhat better than the same rating for CRNX (62) in the Pharmaceuticals Major industry. This means that DNTH’s stock grew somewhat faster than CRNX’s over the last 12 months.

DNTH's SMR Rating (97) in the null industry is in the same range as CRNX (97) in the Pharmaceuticals Major industry. This means that DNTH’s stock grew similarly to CRNX’s over the last 12 months.

DNTH's Price Growth Rating (36) in the null industry is in the same range as CRNX (57) in the Pharmaceuticals Major industry. This means that DNTH’s stock grew similarly to CRNX’s over the last 12 months.

DNTH's P/E Growth Rating (61) in the null industry is somewhat better than the same rating for CRNX (100) in the Pharmaceuticals Major industry. This means that DNTH’s stock grew somewhat faster than CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXDNTH
RSI
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 6 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 6 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EPSPX25.370.02
+0.08%
NYLI Epoch Global Equity Yield Class A
IRVSX26.420.01
+0.04%
Voya Russell Large Cap Value Idx Port S
MLMSX24.67N/A
N/A
Morgan Stanley Instl Global Core R6
TWQCX16.35-0.01
-0.06%
Transamerica Large Cap Value C
SWISX28.35-0.05
-0.18%
Schwab International Index

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+6.35%
XNCR - CRNX
63%
Loosely correlated
-0.67%
DYN - CRNX
57%
Loosely correlated
-1.86%
NUVL - CRNX
57%
Loosely correlated
+2.76%
NRIX - CRNX
57%
Loosely correlated
-2.25%
IDYA - CRNX
56%
Loosely correlated
+0.04%
More

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with XNCR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
+0.29%
XNCR - DNTH
48%
Loosely correlated
-0.67%
CRNX - DNTH
47%
Loosely correlated
+6.35%
EYPT - DNTH
46%
Loosely correlated
+0.22%
IMNM - DNTH
45%
Loosely correlated
+8.09%
OCUL - DNTH
45%
Loosely correlated
+0.41%
More